China supplier new products Agomelatine

  • Purchase Qty: 1
  • Unit: Kg(s)
  • Fob Unit Price: US $100
  • Production Capacity:600kg/month
  • Payment Terms:T/T
  • Favorite
Xi'an Sengmei Biological Technology Co., Ltd

Business Type:Manufacturer

Country/Region:China

Ddu Verified

HOT Rank

8/10

Product Information

  • Active Ingredients:Agomelatine
  • Chemical Formula:C15H17NO2
  • Molecular Weight:243.301
  • Assay:99%
  • Pharmacopeia:CP
  • Package Type:Drum&plastic bags or Aluminum
  • Shelf Life:2 years
  • Storage:Sealed
  • Place of Origin:XI'AN CHINA
  • CAS:138112-76-2

Description

Information

Product name:agomelatine

Synonyms:n-(2-(7-methoxynaphth-1-yl)ethyl)acetamide

CAS No.:138112-76-2

Molecular weight:243.30

Molecular Formula:C15H17NO2

Melting Point:107-109 °C

Boiling point:478.8 °C at 760 mmHg

Appearance:white powder

Competitive price with high quality

Conforms to BP/USP/EP/FCC

 

  Agomelatine is marketed for the treatment of major depressive disorder and has been reported to not produce discontinuation syndrome and have no sexual side effects compared to SSRIs, SNRIs and the older tricyclic antidepressants. Agomelatine may also have positive effects on sleep.

Function

Agomelatine is indicated for the treatment of major depressive episodes in adults.Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder. At the end of treatment, significant efficacy was demonstrated in six of the ten short-term double-blind placebo-controlled studies.Two were considered "failed" trials, as comparators of established efficacy failed to differentiate from placebo. Efficacy was also observed in more severely depressed patients in all positive placebo-controlled studies.The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study.

 

Results of the meta-analysis of three positive, randomized, double-blind, placebo controlled studies in 357 patients treated with agomelatine and 360 patients treated with placebo show that agomelatine is effective in treating severe depression. Its antidepressant effect is greater for more severe depression. In patients with a greater baseline score (>30 on HAMD17 scale), the agomelatine-placebo difference was of 4.53 points.Controlled studies in humans have shown that agomelatine is at least as effective as the SSRI antidepressants paroxetine, sertraline, escitalopram, venlafaxine and fluoxetine in the treatment of major depression.

 

A large meta-analysis of 20 trials with 7460 participants found agomelatine to be as effective as standard antidepressants.

 

A small open-label study has suggested efficacy in the treatment of atypical and melancholic depression.Well-designed clinical trials have demonstrated efficacy in the treatment of anxious depression.Agomelatine’s onset of action has been reported to occur as early as the first week of treatment.

 




You Might Also Like
Change a group
Inquiry Cart(0)